Syra Health Financials
This page shows Syra Health (SYRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Syra Health has an operating margin of -12.5%, meaning the company retains $-13 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -47.2% the prior year.
Syra Health's revenue declined 9.5% year-over-year, from $8.0M to $7.2M. This contraction results in a growth score of 18/100.
Syra Health carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.06, Syra Health holds $4.06 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 80/100.
While Syra Health generated -$448K in operating cash flow, capex of $107 consumed most of it, leaving -$448K in free cash flow. This results in a low score of 10/100, reflecting heavy capital investment rather than weak cash generation.
Syra Health generates a -42.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -130.6% the prior year.
Syra Health passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Syra Health generates $0.50 in operating cash flow (-$448K OCF vs -$896K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Syra Health earns $-68.1 in operating income for every $1 of interest expense (-$904K vs $13K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Syra Health generated $7.2M in revenue in fiscal year 2025. This represents a decrease of 9.5% from the prior year.
Syra Health's EBITDA was -$884K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 76.1% from the prior year.
Syra Health reported -$896K in net income in fiscal year 2025. This represents an increase of 76.2% from the prior year.
Syra Health earned $-0.08 per diluted share (EPS) in fiscal year 2025. This represents an increase of 84.0% from the prior year.
Cash & Balance Sheet
Syra Health generated -$448K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 84.8% from the prior year.
Syra Health held $1.6M in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Syra Health's gross margin was 34.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 13.7 percentage points from the prior year.
Syra Health's operating margin was -12.5% in fiscal year 2025, reflecting core business profitability. This is up 34.7 percentage points from the prior year.
Syra Health's net profit margin was -12.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 34.7 percentage points from the prior year.
Syra Health's ROE was -42.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 87.9 percentage points from the prior year.
Capital Allocation
Syra Health invested $68K in research and development in fiscal year 2025. This represents a decrease of 88.4% from the prior year.
Syra Health invested $107 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 99.0% from the prior year.
SYRA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M+2.7% | $1.7M-13.3% | $1.9M+4.8% | $1.9M-7.4% | $2.0M-10.9% | $2.3M+14.4% | $2.0M+12.4% | $1.8M |
| Cost of Revenue | $1.1M+0.8% | $1.1M-5.0% | $1.2M-5.9% | $1.3M-24.1% | $1.7M+5.5% | $1.6M-2.1% | $1.6M+11.5% | $1.5M |
| Gross Profit | $591K+6.6% | $555K-26.3% | $753K+27.8% | $589K+75.9% | $335K-49.9% | $668K+90.9% | $350K+16.8% | $300K |
| R&D Expenses | $139-83.0% | $816-97.3% | $30K-20.1% | $37K+826.5% | -$5K-114.7% | $35K-87.5% | $278K+0.1% | $278K |
| SG&A Expenses | $237K-6.2% | $252K-12.7% | $289K+0.6% | $287K+61.8% | $178K-38.4% | $288K-36.9% | $457K-12.7% | $523K |
| Operating Income | -$136K+41.6% | -$232K-267.6% | -$63K+86.7% | -$473K+5.6% | -$502K-17.0% | -$429K+69.2% | -$1.4M+3.7% | -$1.4M |
| Interest Expense | $4K+124.6% | $2K-50.6% | $4K+19.5% | $3K-41.6% | $6K+144.0% | $2K-39.2% | $4K-8.5% | $4K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$135K+40.4% | -$226K-255.2% | -$64K+86.5% | -$472K+6.4% | -$504K-20.8% | -$418K+70.0% | -$1.4M+3.9% | -$1.4M |
| EPS (Diluted) | N/A | $-0.02-100.0% | $-0.01+75.0% | $-0.04 | N/A | $-0.06+71.4% | $-0.21+4.5% | $-0.22 |
SYRA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.8M-15.0% | $3.3M-6.0% | $3.5M-6.7% | $3.7M+1.2% | $3.7M-16.9% | $4.4M+36.6% | $3.2M-28.9% | $4.6M |
| Current Assets | $2.7M-14.7% | $3.2M-6.5% | $3.4M-5.8% | $3.6M+8.8% | $3.4M-17.5% | $4.1M+43.8% | $2.8M-36.4% | $4.4M |
| Cash & Equivalents | $1.6M-18.3% | $2.0M-14.3% | $2.3M-7.4% | $2.5M+4.0% | $2.4M-11.2% | $2.7M+69.2% | $1.6M-50.8% | $3.2M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $918K-0.9% | $926K+4.5% | $886K | N/A | $681K+12233.8% | $6K0.0% | $6K0.0% | $6K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $675K-36.0% | $1.1M-0.3% | $1.1M-16.5% | $1.3M+58.1% | $801K-26.8% | $1.1M-4.5% | $1.1M+4.0% | $1.1M |
| Current Liabilities | $675K-36.0% | $1.1M-0.3% | $1.1M-16.5% | $1.3M+106.3% | $614K-30.1% | $878K-2.6% | $901K-18.2% | $1.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.1M-5.0% | $2.2M-8.5% | $2.4M-1.7% | $2.5M-14.7% | $2.9M-13.6% | $3.3M+59.2% | $2.1M-39.3% | $3.4M |
| Retained Earnings | -$9.7M-1.4% | -$9.6M-2.4% | -$9.4M-0.7% | -$9.3M-5.4% | -$8.8M-6.1% | -$8.3M-5.3% | -$7.9M-21.3% | -$6.5M |
SYRA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$289K-18.4% | -$244K-237.1% | -$72K-145.8% | $158K+173.7% | -$215K+48.0% | -$413K+72.5% | -$1.5M-87.7% | -$801K |
| Capital Expenditures | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $5K-2.3% | $6K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$215K+48.0% | -$413K+72.6% | -$1.5M-87.1% | -$806K |
| Investing Cash Flow | N/A | N/A | N/A | N/A | $0 | $0+100.0% | -$5K+2.3% | -$6K |
| Financing Cash Flow | -$73K+14.8% | -$85K+24.2% | -$112K-77.9% | -$63K+27.8% | -$87K-105.8% | $1.5M+1224.5% | -$135K-117.6% | $764K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SYRA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 34.1%+1.2pp | 32.9%-5.8pp | 38.7%+7.0pp | 31.7%+15.0pp | 16.7%-13.0pp | 29.7%+11.9pp | 17.8%+0.7pp | 17.1% |
| Operating Margin | -7.8%+5.9pp | -13.8%-10.5pp | -3.3%+22.2pp | -25.5%-0.5pp | -25.0%-6.0pp | -19.0%+51.6pp | -70.6%+11.8pp | -82.4% |
| Net Margin | -7.8%+5.6pp | -13.4%-10.1pp | -3.3%+22.1pp | -25.4%-0.3pp | -25.1%-6.6pp | -18.5%+52.0pp | -70.6%+12.0pp | -82.6% |
| Return on Equity | -6.4%+3.8pp | -10.2%-7.6pp | -2.6%+16.6pp | -19.2%-1.7pp | -17.5%-5.0pp | -12.5%+53.9pp | -66.5%-24.5pp | -41.9% |
| Return on Assets | -4.9%+2.1pp | -6.9%-5.1pp | -1.8%+10.9pp | -12.7%+1.0pp | -13.7%-4.3pp | -9.4%+33.5pp | -42.9%-11.1pp | -31.8% |
| Current Ratio | 4.06+1.0 | 3.05-0.2 | 3.25+0.4 | 2.88-2.6 | 5.46+0.8 | 4.63+1.5 | 3.14-0.9 | 4.04 |
| Debt-to-Equity | 0.32-0.2 | 0.48+0.0 | 0.44-0.1 | 0.52+0.2 | 0.28-0.1 | 0.33-0.2 | 0.55+0.2 | 0.32 |
| FCF Margin | N/A | N/A | N/A | N/A | -10.7%+7.6pp | -18.3%+58.3pp | -76.6%-30.6pp | -46.0% |
Similar Companies
Frequently Asked Questions
What is Syra Health's annual revenue?
Syra Health (SYRA) reported $7.2M in total revenue for fiscal year 2025. This represents a -9.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Syra Health's revenue growing?
Syra Health (SYRA) revenue declined by 9.5% year-over-year, from $8.0M to $7.2M in fiscal year 2025.
Is Syra Health profitable?
No, Syra Health (SYRA) reported a net income of -$896K in fiscal year 2025, with a net profit margin of -12.4%.
What is Syra Health's EBITDA?
Syra Health (SYRA) had EBITDA of -$884K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Syra Health's gross margin?
Syra Health (SYRA) had a gross margin of 34.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Syra Health's operating margin?
Syra Health (SYRA) had an operating margin of -12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Syra Health's net profit margin?
Syra Health (SYRA) had a net profit margin of -12.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Syra Health's return on equity (ROE)?
Syra Health (SYRA) has a return on equity of -42.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Syra Health's free cash flow?
Syra Health (SYRA) generated -$448K in free cash flow during fiscal year 2025. This represents a 84.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Syra Health's operating cash flow?
Syra Health (SYRA) generated -$448K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Syra Health's total assets?
Syra Health (SYRA) had $2.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Syra Health's capital expenditures?
Syra Health (SYRA) invested $107 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Syra Health spend on research and development?
Syra Health (SYRA) invested $68K in research and development during fiscal year 2025.
What is Syra Health's current ratio?
Syra Health (SYRA) had a current ratio of 4.06 as of fiscal year 2025, which is generally considered healthy.
What is Syra Health's debt-to-equity ratio?
Syra Health (SYRA) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Syra Health's return on assets (ROA)?
Syra Health (SYRA) had a return on assets of -32.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Syra Health's cash runway?
Based on fiscal year 2025 data, Syra Health (SYRA) had $1.6M in cash against an annual operating cash burn of $448K. This gives an estimated cash runway of approximately 43 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Syra Health's Piotroski F-Score?
Syra Health (SYRA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Syra Health's earnings high quality?
Syra Health (SYRA) has an earnings quality ratio of 0.50x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Syra Health cover its interest payments?
Syra Health (SYRA) has an interest coverage ratio of -68.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Syra Health?
Syra Health (SYRA) scores 34 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.